anaplastic ependymoma (Cancer)
Information
- Disease name
- anaplastic ependymoma
- Disease ID
- DOID:5889
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02101905 | Active, not recruiting | Phase 1 | Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma | March 13, 2014 | October 19, 2024 |
| NCT01096368 | Active, not recruiting | Phase 3 | Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma | May 7, 2010 | September 22, 2024 |
| NCT01082926 | Completed | Phase 1 | Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2 | May 2010 | September 2013 |
| NCT03434262 | Completed | Phase 1 | SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors | March 5, 2018 | May 24, 2024 |
| NCT01295944 | Completed | Phase 2 | Carboplatin and Bevacizumab for Recurrent Ependymoma | April 27, 2011 | May 14, 2021 |
| NCT05278208 | Recruiting | Phase 1/Phase 2 | Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors | November 21, 2022 | November 2027 |
| NCT03750513 | Recruiting | Phase 1 | LET Optimized IMPT in Treating Pediatric Patients With Ependymoma | April 1, 2019 | December 31, 2027 |
| NCT04978727 | Recruiting | Phase 1 | A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma | July 1, 2022 | June 30, 2028 |
| NCT01836549 | Terminated | Phase 2 | Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors | March 2013 | April 2016 |
| NCT01721577 | Terminated | Phase 1/Phase 2 | Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant Astrocytomas | December 2012 | December 2015 |
| NCT03727841 | Terminated | Phase 2 | Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma | January 22, 2020 | April 30, 2021 |
| NCT02722512 | Terminated | Phase 1 | Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine | July 2016 | November 13, 2019 |
| NCT01095094 | Terminated | Phase 2 | Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma | January 2009 | November 2011 |
| NCT00243490 | Withdrawn | Phase 2 | Photodynamic Therapy in the Treatment of Malignant Intracranial Tumors | January 2009 | |
| NCT04521946 | Withdrawn | Phase 1 | Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer | January 14, 2021 | December 20, 2022 |
- Disase is a (Disease Ontology)
- DOID:5074
- Cross Reference ID (Disease Ontology)
- ICDO:9392/3
- Exact Synonym (Disease Ontology)
- Ependymoma, anaplastic
- Exact Synonym (Disease Ontology)
- Undifferentiated Ependymoma
- OrphaNumber from OrphaNet (Orphanet)
- 251646